Accendra Health, Inc.
ACH
NYSE·Healthcare·Medical - Distribution·Mkt cap $92.7M
$1.21
▼ -0.82%
P/E
—
Mkt Cap
$92.7M
52-Wk Range
$0.93–$5.69
52-Week Range
$0.93 - $5.69
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 77.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive distribution network and long-standing relationships with multi-facility healthcare networks and independent providers
- Proprietary products and branded portfolio creating differentiation and pricing power in commoditized medical supplies
- Data analytics and supply chain optimization capabilities providing recurring revenue and customer stickiness
- Integrated dual-channel model combining B2B healthcare services with direct-to-patient home care, reducing competition and capturing multiple margin layers
Bear Case
2 risks
- Above-average volatility (beta 1.5).
- Extreme premium - high expectations embedded
Growth
Turning profitable
Shift toward home-based and outpatient care reducing hospital utilization and driving demand for Patient Direct segment products
Value
Extreme premium - high expectations embedded
Momentum
Falling
-52.5% over 3m
Quality
Strong
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying ACH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
AUG 10, 2026
Reported EPS of -$0.19 vs -$0.08 consensus (-126.7% surprise). Revenue of $613.2M vs $628.7M expected (-2.5%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-126.7%
Revenue trend · last 8Q
—
—
+1%
+3%
+2%
-74%
-76%
-10%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$686.8M
$2.7B
$2.6B
$681.9M
$697.3M
$709.0M
$627.8M
$613.2M
Margins · last 8Q
Gross
43.0%
Operating
-5.7%
Profit
-14.5%
Wall Street consensus
6 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
17%
Sell
33%
Median Price Target
—
Latest: Citi · Aug 10, 2026
vs Industry
How ACH stacks vs Medical - Distribution
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related